A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Revenue
â‚©24.4B
CAGR 3-Years
89%
CAGR 5-Years
129%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Revenue
â‚©2.9T
CAGR 3-Years
17%
CAGR 5-Years
24%
CAGR 10-Years
23%
SK Bioscience Co Ltd
KRX:302440
Revenue
â‚©369.5B
CAGR 3-Years
18%
CAGR 5-Years
30%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Revenue
â‚©363.8B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Revenue
â‚©317B
CAGR 3-Years
30%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Revenue
â‚©74.4B
CAGR 3-Years
36%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Revenue?
Revenue
24.4B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Revenue amounts to 24.4B KRW.

What is ABL Bio Inc's Revenue growth rate?
Revenue CAGR 5Y
129%

Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for ABL Bio Inc have been 89% over the past three years , 129% over the past five years .

Back to Top